Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155

Benzinga · 05/07 17:37
Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $167 to $155.